Reducing the CNS reservoir through myeloid cell depletion

通过耗竭骨髓细胞减少中枢神经系统储库

基本信息

  • 批准号:
    10254688
  • 负责人:
  • 金额:
    $ 21.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT HIV infection results in CNS comorbidities, with nearly 75% of patients with advanced HIV disease showing neurological manifestations. The blood-brain barrier prevents antiretroviral drugs from entering the CNS, and thus a reservoir occurs. Macrophage and microglia remain at least latently infected, awaiting an insult to reawaken. A recently FDA-approved drug, Pexidartinib, has been used to safely deplete microglia and macrophages. These microglia are believed to repopulate from the subventricular zone, with initial cells being CD4-ve. This could render these cells impervious to infection. Further, SIV infection makes macrophages resistant to apoptosis: Pexidartinib restores this apoptotic sensitivity. This could provide an avenue to examining the depletion of latently infected cells from the CNS, with the potential for diminishing later neurological disorders, including the major CNS comorbidity: HAND. There is debate that latently-infected microglia and macrophages can be a source of viral rebound to the periphery. Removing those microglia after viral setpoint, with macaques on stable cART, and determining if the CNS reservoir can return, could answer this very question. The effects of transiently depleting microglia from the CNS, especially in the context of SIV infection, represent a significant gap in our knowledge. Therefore, there is a critical need to understand the effects of transiently removing latently-infected microglia from the CNS in SIV neuropathology. This R21 application seeks to address how removing microglia from the CNS influences neuroinflammation both positively and negatively in the context of SIV infection.
项目总结/摘要 HIV感染导致CNS合并症,近75%的晚期HIV患者表现出 神经学表现血脑屏障阻止抗逆转录病毒药物进入CNS, 从而形成储层。巨噬细胞和小胶质细胞至少保持潜伏感染,等待对 重新醒来最近FDA批准的药物Pexidartinib已被用于安全地消耗小胶质细胞, 巨噬细胞这些小胶质细胞被认为是从脑室下区重新增殖的,初始细胞是 CD4-ve。这可以使这些细胞不受感染。此外,SIV感染使巨噬细胞 抗凋亡:Pexidartinib可恢复这种凋亡敏感性。这可以提供一种途径, 从中枢神经系统中清除潜伏感染细胞,具有减少后期神经系统疾病的潜力, 包括主要的CNS合并症:手。 有争议的是,潜在感染的小胶质细胞和巨噬细胞可能是病毒反弹到 外围。在病毒设定点后去除那些小胶质细胞,猕猴进行稳定的cART,并确定是否存在病毒。 中枢神经系统的储库可以恢复,可以回答这个问题。短暂消耗小胶质细胞的影响, 中枢神经系统,特别是在SIV感染的情况下,代表了我们知识的一个重大空白。因此有 迫切需要了解从SIV的CNS中暂时去除潜伏感染的小胶质细胞的效果 神经病理学这项R21申请旨在解决从CNS中去除小胶质细胞如何影响 SIV感染的背景下,神经炎症的积极和消极。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW G MACLEAN其他文献

ANDREW G MACLEAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW G MACLEAN', 18)}}的其他基金

Reducing the CNS reservoir through myeloid cell depletion
通过耗竭骨髓细胞减少中枢神经系统储库
  • 批准号:
    10452642
  • 财政年份:
    2021
  • 资助金额:
    $ 21.25万
  • 项目类别:
Exploratory Research on HIV Contribution to Heart and Lung Comorbidities
HIV 对心肺合并症影响的探索性研究
  • 批准号:
    10012373
  • 财政年份:
    2020
  • 资助金额:
    $ 21.25万
  • 项目类别:
Exploratory Research on HIV Contribution to Heart and Lung Comorbidities
HIV 对心肺合并症影响的探索性研究
  • 批准号:
    10569641
  • 财政年份:
    2020
  • 资助金额:
    $ 21.25万
  • 项目类别:
Exploratory Research on HIV Contribution to Heart and Lung Comorbidities
HIV 对心肺合并症影响的探索性研究
  • 批准号:
    10343825
  • 财政年份:
    2020
  • 资助金额:
    $ 21.25万
  • 项目类别:
S100BETA AS A DETERMINANT FOR DEVELOPMENT OF MONOCYTE-DRIVEN ENCEPHALITIS
S100BETA 作为单核细胞驱动性脑炎发展的决定因素
  • 批准号:
    8358083
  • 财政年份:
    2011
  • 资助金额:
    $ 21.25万
  • 项目类别:
PRODUCTION OF CCL7 BY ASTROCYTES: SIV NEUROINVASION AND AIDS ENCEPHALITIS
星形胶质细胞产生 CCL7:SIV 神经侵袭和艾滋病脑炎
  • 批准号:
    8358099
  • 财政年份:
    2011
  • 资助金额:
    $ 21.25万
  • 项目类别:
DYMANICS OF ENDOTHELIAL CELL SIGNALING AND SIVE NEUROINFLAMMATION
内皮细胞信号传导和严重神经炎症的动力学
  • 批准号:
    8358124
  • 财政年份:
    2011
  • 资助金额:
    $ 21.25万
  • 项目类别:
INTERMEDIATE FILAMENT EXPRESSION IN ASTROCYTES
星形胶质细胞中的中间丝表达
  • 批准号:
    8358123
  • 财政年份:
    2011
  • 资助金额:
    $ 21.25万
  • 项目类别:
S100BETA, AS A DETERMINANT FOR DEVELOPMENT OF MONOCYTE-DRIVEN ENCEPHALITIS
S100BETA,作为单核细胞驱动性脑炎发展的决定因素
  • 批准号:
    8172980
  • 财政年份:
    2010
  • 资助金额:
    $ 21.25万
  • 项目类别:
FOCAL ADHESION KINASE ACTIVATION IN THE BLOOD-BRAIN BARRIER
血脑屏障中的局部粘附激酶激活
  • 批准号:
    8172964
  • 财政年份:
    2010
  • 资助金额:
    $ 21.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了